Copernicus Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Copernicus Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$850K	Buy	+11,000	New	+$868K	10.29%	4
2021 Q2	–	Sell	-10,000	Closed	-$755K	–	14
2021 Q1	$755K	Sell	10,000 -719	-7%	-$58.7K	12.2%	1
2020 Q4	$940K	Sell	10,719 -154,462	-94%	-$12.2M	14.65%	1
2020 Q3	$12.6M	Buy	165,181 +115,292	+231%	+$11.7M	11.97%	3
2020 Q2	$6.15M	Sell	49,889 -53,290	-52%	-$5.3M	6.74%	6
2020 Q1	$8.72M	Sell	103,179 -20,779	-17%	-$1.79M	10.55%	4
2019 Q4	$10.5M	Sell	123,958 -12,042	-9%	-$910K	13.74%	2
2019 Q3	$9.17M	Buy	+136,000	New	+$10.5M	8.53%	5

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Copernicus Capital Management's BMRN Position: Q3 2021 in Review

Copernicus Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2021: 11,000 shares worth $850K. The stake represents 10.29% of the portfolio and ranks #4 among its holdings. This is a return to the name: Copernicus Capital Management previously reported a position in BMRN as recently as Q1 2021.

Copernicus Capital Management first reported a position in BMRN in Q3 2019 and has held it in 8 quarters since. The position peaked at $12.6M in Q3 2020. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Copernicus Capital Management held 11,000 shares of BioMarin Pharmaceuticals worth $850K as of Q3 2021.
BioMarin Pharmaceuticals was a new Copernicus Capital Management position in Q3 2021.
BioMarin Pharmaceuticals made up 10.29% of Copernicus Capital Management's portfolio in Q3 2021, its #4 holding.
Copernicus Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2019 and has held it in 8 quarters since.
Copernicus Capital Management's BioMarin Pharmaceuticals position peaked at $12.6M in Q3 2020.
511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.